Certification of AESKULISA® SARS-CoV-2 S1 IgG and IgM for SARS-CoV-2
Keywords:
AESKU, certification, COVID-19, SARS-CoV-2, spike antibodiesAbstract
Validation of immunoassay kits of different methodologies such as enzyme-linked immunosorbent assay (ELISA), IFA immunofluorescence analyses, chemiluminescent immunoassay (CLIA), among others; under national and international certification protocols, it is one of the steps to obtain the sanitary registry before the Ministry of Popular Power for Health; and thus be able to be marketed in the Venezuelan territory. The objective is to verify the performance characteristics established by the manufacturer and to evaluate the performance of said methodologies. For this reason, this article shows a retrospective study, which determined the diagnostic performance of two ELISA methodology kits from the AESKU® commercial house for the detection of IgG and IgM spike (S1) antibodies in patients with the SARS-CoV-2 virus, used at autonomous institute university hospital of the Andes. For statistical processing, the SPSS IBM 16® statistical software was used. The results obtained were for S1 IgG: 97,33 % precision > 99 % accuracy, 93,78 % sensitivity, and > 99 % specificity; and for the S1 IgM precision of 94,20 %, accuracy > 99 %, sensitivity 96,51 % and specificity 92,85 %. This corroborates that the characteristics reflected in the documents issued by the manufacturer of AESKULISA® SARS-CoV-2 S1 IgG and IgM in terms of quality, accuracy, precision, sensitivity and specificity, are optimal for the determination of S1 IgG spike antibodies and IgM against SARS-CoV-2 in human serum or plasma.
Downloads
References
Aesku Diagnostics. (2020). Manual de instrucciones. Wendelsheim.
Behnke, G. (2019). Validación del kit de benzodiazepinas ELISA de Neogen usando clonazepam como molécula diana para sangre y orina. Revista de Toxicología Analítica, 1-7.
Braun, L. y Frentsch, G. (2020). Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors. Nature.
Chen, Zhou, Dong, Qu, Gong, & Han (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet, 507-13.
CLSI (2014). Verificación del usuario y la estimación del sesgo. Wayne: CLSI. Documento EP 15-A3.
Abebe, E.; Dejenie, T.; Shiferaw, M.; Malik, T. (2020). The newly emerged COVID-19 disease: a systemic review. Virol, 17.
Gaudin, V. (2013). Validation of two ELISA kits for the screening of tylosin and streptomycin in honey according to the European decision 2002/657/EC. Taylor & Francis group, 93-109.
Grifoni, Weiskropf, Ramirez, Mateus, Dan, & Moderbacher (2020). Targets of T Cell Responses to SARS-CoV-2 °Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 1489-501.
Hoffmam, Klein, Schroeder, Kruger, Herrler, & Erichsen (2020). SARS-CoV-2 °Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 271-80.
Lecturio (2022). Lecturio. Retrieved from https://www.lecturio.com/es/concepts/inmunoensayos/MPPS. (1999). Resolución Nº 55 (Gaceta Oficial Nº 36.843 del 3 de diciembre de 1999). Caracas: MPPS.
Ni, Ye, Cheng, Feng, Deng, & Zhao (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 °Convalescent Individuals. Immunity, 971-7.
Odax, Barros-Martins, Bosnjak, Stahl, & Wiesner (2020). Reappearance of effector T cells is associated with recovery from COVID-19. EbioMedicine.
OMS (2020). Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. Geneva: WHO/BS/2020.2403.
Ou, Liu, Lei, Li, Mi, & Ren, et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV-2. Nat Commun., 1620.
Peiris, Lai, Poon, Guan, Yam, & Lim (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet.
Petherick, A. (2020). Developing antibody tests for SARS-CoV-2. Lancet, 1101-2.
Ruisánchez, I. (2010). Validación de métodos analíticos cualitativos. Departamento de Química Analítica y Química, 1-11.
Thevarajan, Nguyen, Koutsakos, Druce, Caly, & Van de Sandt (2020). Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med, 453-5.
Tre-Hardy, M. (2020). Validación de un ensayo quimioluminiscente para anticuerpos específicos contra el SARS-CoV-2. Clin Chem Lab Med, 1357–1364.
Zhu, Zhang, Wang, Li, Yam, & Lim. (2019). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 727-33
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
